Figure 3 | Scientific Reports

Figure 3

From: Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

Figure 3Figure 3

Kaplan–Meier curve according to major epidermal growth factor receptor (EGFR) mutation (A) and T790M (B) at pretreatment, 1 month, and progressive disease (PD) after osimertinib administration. Patients with detection of major EGFR mutation at pretreatment exhibited a significantly shorter progression-free survival (PFS) than those without it; moreover, there was significantly worse overall survival (OS) in patients with detection of major EGFR mutation at PD than those without it (A). Patients with T790M detection at PD yielded significantly worse PFS and OS than those without it (B).

Back to article page